New Clinical Research Hub Launched by Thermo Fisher in Wisconsin
Thermo Fisher expands clinical lab in Wisconsin for advanced drug development services
Breaking News
Jun 19, 2024
Mrudula Kulkarni
Thermo Fisher Scientific Inc.'s PPD clinical research
division has opened a new 72,500-square-foot clinical research laboratory at
its GMP facility in Middleton, Wisconsin. This expansion enhances the site's
CMC analytical capabilities, supporting its clinical development and laboratory
services aimed at advancing health by assisting clients in bringing
transformative medications to market.
Leon Wyszkowski, president, analytical services, clinical
research, Thermo Fisher Scientific, said in a statement, “As research in
bio-pharmaceutical therapies continues to rapidly expand, we are excited to
expand our overall capacity and capabilities in laboratory services to help our
customers deliver therapies that meet the highest quality and safety standards
for patients. This $58 million investment to expand the site is a testament to
our dedication in supporting Thermo Fisher’s Mission of making the world
healthier, cleaner and safer.”
The GMP facility provides analytical services for small
molecules and biologics, including biopharmaceuticals, inhaled pharmaceuticals,
and device testing, as well as cell and gene therapy, protein characterization,
and mass spectrometry analysis throughout all stages of drug development.
The recent expansion at the GMP campus includes a versatile
biosafety level 2 laboratory, specially designed spaces for liquid
chromatography-mass spectrometry and protein characterization, two extensive
molecular suites with controlled access pre- and post-amplification labs, and
two large general-purpose labs. This addition will bring up to 350 scientists
and laboratory support staff, complementing the nearly 2,300 employees already
at the research campus.